With GLP-1 medications, the lean mass loss appears to exceed what is typically expected and the reasons are straightforward: these medications dramatically reduce appetite, which means many users eat significantly less food overall
Whereas pharmacotherapeutic and other interventions have steadily improved the prognosis of other types of cardiovascular disease (CVD) and associated sequelae, HF remains associated with more pronounced morbidity and mortality, constituting one of the most pronounced unmet needs in cardiovascular medicine (Shah et al., 2020)
Addendum J to this final rule with comment period also contains summary cost statistics for each of the paired code combinations that describe a complex code combination that would qualify for a complexity adjustment and be reassigned to the next higher cost C-APC within the clinical family
Scrocchi LA, Drucker DJ
While it may not cross the blood-brain barrier as aggressively as ALCAR, its ability to simultaneously deliver fatty acids and a direct Krebs cycle intermediate makes it unparalleled for supporting sustained cardiovascular energy, systemic endurance, and mitochondrial ATP production
However, many patients regain weight after stopping these medications and hence discussion needs to happen with your healthcare provider before stopping so that other interventions including diet and exercise are optimized
